PFG Investments LLC Acquires Shares of 3,274 GeneDx Holdings Corp. (NASDAQ:WGS)

PFG Investments LLC bought a new position in GeneDx Holdings Corp. (NASDAQ:WGS) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 3,274 shares of the company’s stock, valued at approximately $252,000.

A number of other large investors have also recently modified their holdings of the stock. MCF Advisors LLC lifted its holdings in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after buying an additional 182 shares during the period. CWM LLC purchased a new position in shares of GeneDx in the 3rd quarter valued at approximately $89,000. Evolution Wealth Advisors LLC bought a new stake in shares of GeneDx during the fourth quarter valued at approximately $202,000. Verition Fund Management LLC grew its stake in GeneDx by 12.9% in the third quarter. Verition Fund Management LLC now owns 25,845 shares of the company’s stock worth $1,097,000 after purchasing an additional 2,945 shares during the period. Finally, SG Americas Securities LLC raised its holdings in GeneDx by 87.2% in the fourth quarter. SG Americas Securities LLC now owns 8,735 shares of the company’s stock worth $671,000 after purchasing an additional 4,068 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 22,307 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $70.34, for a total value of $1,569,074.38. Following the transaction, the chief executive officer now directly owns 60,011 shares in the company, valued at $4,221,173.74. This trade represents a 27.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $70.78, for a total value of $8,973,629.96. Following the sale, the insider now owns 2,719,692 shares of the company’s stock, valued at approximately $192,499,799.76. This trade represents a 4.45 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 363,669 shares of company stock worth $28,061,081. 27.30% of the stock is owned by corporate insiders.

GeneDx Price Performance

Shares of WGS opened at $74.85 on Friday. GeneDx Holdings Corp. has a twelve month low of $3.62 and a twelve month high of $98.87. The company has a market capitalization of $2.06 billion, a P/E ratio of -24.07 and a beta of 2.02. The firm has a 50 day moving average of $78.29 and a 200 day moving average of $57.97. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business had revenue of $76.90 million during the quarter, compared to analyst estimates of $64.98 million. During the same quarter last year, the company earned ($0.82) EPS. The company’s quarterly revenue was up 44.3% compared to the same quarter last year. As a group, equities research analysts anticipate that GeneDx Holdings Corp. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on WGS. Wells Fargo & Company boosted their target price on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Craig Hallum upped their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. TD Cowen lifted their target price on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, January 7th. Finally, The Goldman Sachs Group upped their price target on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus target price of $70.67.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.